Pure Global: Brazil's AI Diagnostic Maze, Cracking ANVISA's New Rules

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Unfollow podcast failed

Pure Global: Brazil's AI Diagnostic Maze, Cracking ANVISA's New Rules

Listen for free

View show details

About this listen

In this episode of LATAM MedTech Insights, we dissect the groundbreaking new regulation from Brazil's ANVISA, RDC 922/2026, which just rewrote the rules for AI-powered medical software. This isn't just an update; it's a seismic shift that introduces mandatory local clinical data requirements, impacting market access timelines and costs for foreign manufacturers. We explore the immediate consequences for MedTech innovators, especially those relying on existing FDA or CE Mark approvals. Learn what this increased scrutiny means for your product's classification, the validation process, and your overall launch strategy in Latin America's largest market. **Case In Point:** A promising US-based AI diagnostics company had their Brazilian launch plans shattered overnight by the new RDC 922. Their reliance on FDA clinical data is no longer enough, forcing them into an unexpected, costly, and lengthy local clinical study. Their entire LATAM expansion is now in jeopardy, a stark reminder that global regulatory approvals don't guarantee local market access. **This Episode's Key Questions:** - How does ANVISA's new RDC 922/2026 specifically reclassify AI diagnostic software? - Are my existing FDA or CE Mark clinical studies now invalid for a Brazilian submission? - What are the new mandatory requirements for local clinical data from the Brazilian population? - How will this regulatory shift impact the cost and timeline for market entry into Brazil? - What are the critical mistakes to avoid when adapting your technical dossier for this new framework? - Could this new Brazilian regulation signal a coming trend for other LATAM markets like Mexico or Colombia? - How can you turn this regulatory hurdle into a competitive advantage? Navigating complex, sudden regulatory changes is our specialty. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline global market access for MedTech and IVD companies. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your path to market.

No reviews yet